Carestream Health Inc.: When Disruption Hits a Lean Supply Chain Custom Case Solution & Analysis

1. Evidence Brief: Case Researcher

Financial Metrics

• Annual Revenue: Approximately 2.4 billion dollars at the time of the incident.
• Inventory Strategy: Lean methodology focused on minimizing carrying costs and maximizing turnover.
• Market Position: Carestream held significant global market share in medical film and digital imaging.
• Impact Cost: Potential loss of revenue if supply of Triacetyl Cellulose (TAC) film remains halted for more than 30 days.

Operational Facts

• Product Dependency: Medical film production relies heavily on TAC, a specialized chemical substrate.
• Supplier Geography: Primary suppliers for TAC and critical chemicals are concentrated in Japan, specifically near the earthquake epicenter.
• Logistics Status: Post-earthquake infrastructure damage in Japan limited transport from factories to ports.
• Supply Chain Philosophy: Just-in-time (JIT) delivery models meant that on-site safety stock was kept at minimal levels to ensure lean operations.
• Production Capacity: Carestream manufacturing facilities in the United States and China require consistent raw material inputs to maintain output.

Stakeholder Positions

• Supply Chain Leadership: Focused on immediate inventory visibility and identifying alternative shipping routes.
• Japanese Suppliers: Facing force majeure conditions, unable to provide firm restart dates for production lines.
• Healthcare Providers: Hospitals and clinics require medical film for diagnostic purposes; demand is inelastic and urgent.
• Competitors: Fujifilm and Konica Minolta are both competitors and, in some instances, providers of raw materials or finished goods.

Information Gaps

• Exact inventory levels at every Tier 2 and Tier 3 supplier node are not fully transparent.
• The precise timeline for power grid stabilization in the impacted Japanese regions is unknown.
• The feasibility of substituting TAC with alternative materials without compromising diagnostic image quality is unverified.

2. Strategic Analysis: Market Strategy Consultant

Core Strategic Question

• How can Carestream Health mitigate the immediate collapse of its lean supply chain while transitioning to a resilient model that prevents future single-point-of-failure disruptions?

Structural Analysis

The medical imaging industry faces a structural crisis where supplier power is absolute. In the TAC market, high capital requirements and specialized chemistry create an oligopoly. The earthquake transformed a lean advantage into a liability. Porter’s Five Forces reveals that supplier power is currently the dominant force, as Carestream has no immediate substitutes for Japan-sourced TAC. The internal value chain is broken at the procurement stage, halting downstream manufacturing and sales.

Strategic Options

Preliminary Recommendation

Carestream must pursue a dual-track strategy. In the short term, implement a strict demand-allocation model to preserve existing stock for high-priority clinical needs. Simultaneously, the company must end its reliance on single-sourced Japanese chemicals by qualifying at least one secondary supplier in a different geographic region. The lean model failed because it ignored tail-risk; resilience must now be priced into the supply chain cost structure.

3. Implementation Roadmap: Operations Specialist

Critical Path

• Week 1: Establish a Global Crisis Command Center. Map every Tier 1 and Tier 2 supplier to identify specific nodes of failure.
• Weeks 2-4: Initiate emergency qualification of alternative chemical suppliers in Europe or North America. Secure air-freight capacity for remaining Japanese inventory.
• Month 2: Implement a customer priority matrix. Allocate film based on medical necessity rather than order volume.
• Month 3: Renegotiate supplier contracts to include mandatory geographic diversification and minimum safety stock levels held at Carestream sites.

Key Constraints

• Technical Specification: Medical film chemistry is precise. Any variation from alternative suppliers could lead to artifacts in diagnostic images, creating legal and safety risks.
• Regulatory Approval: Changes in raw material sources may require re-certification by health authorities in various jurisdictions, slowing the transition.

Risk-Adjusted Implementation Strategy

The primary risk is a prolonged recovery of the Japanese power grid. To mitigate this, the implementation plan assumes a 6-month disruption. We will bypass damaged Japanese ports by utilizing truck transport to southern ports that remain operational. A 15 percent price premium is authorized for spot-market chemical purchases to ensure continuity. Contingency plans include a temporary reduction in product variety to focus all manufacturing capacity on the highest-volume, most critical film types.

4. Executive Review and BLUF: Senior Partner

BLUF

Carestream must immediately abandon its current lean configuration for critical raw materials. The 2011 earthquake exposed a structural fragility: the concentration of specialized TAC production in a single seismic zone. We will implement a 90-day inventory buffer for all non-substitutable components and qualify a secondary geographic source for TAC. This transition will increase annual holding costs by 4 million dollars but protects 2.4 billion dollars in revenue. The priority is survival through allocation, followed by a permanent shift to a resilient supply chain architecture.

Dangerous Assumption

The analysis assumes that customers will remain loyal during a film shortage. If competitors with digital solutions or better-stocked film inventories move in, Carestream may face a permanent loss of market share that cannot be recovered once supply stabilizes.

Unaddressed Risks

• Financial Risk: The cost of emergency air-freight and spot-market procurement may significantly erode margins for the fiscal year, potentially triggering debt covenant issues.
• Operational Risk: Rapidly qualifying new suppliers may lead to a higher rate of product defects, resulting in costly recalls and damage to the brand reputation in the medical community.

Unconsidered Alternative

The team did not fully explore a strategic partnership or joint venture with a competitor to share the cost of developing a new, geographically diverse TAC production facility. While this involves sharing intellectual property, it would distribute the massive capital expenditure required to build a resilient supply base for a declining but still profitable film market.

Verdict

APPROVED FOR LEADERSHIP REVIEW